Humacyte Inc (HUMAW)
Official siteBIOTECHNOLOGY • NASDAQ
Last updated: Aug 26, 2026 at 5:00 PM ET
Humacyte Inc (HUMAW) Financials: Revenue, Profit and Cash Flow
Humacyte reported revenue of $2.04M for the fiscal year ended Dec 31, 2025. That year, net income was -$40.83M with a net margin of -2003.6%, operating cash flow was -$105.04M and free cash flow was -$105.93M. The quarter ended Jun 30, 2026 had revenue of $406.00K and net income of -$36.80M.
Revenue and Margins
Over the 6 years to Dec 2025, revenue fell from $6.19M, a compound annual decline of 16.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.04M | N/A | -736.5% | -5271.7% | -2003.6% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $1.56M | +23.9% | -427.5% | -5404.3% | -764.5% |
| Dec 2021 | $1.26M | -15.3% | -4756.8% | -6429.8% | -2096.4% |
| Dec 2020 | $1.49M | -75.9% | -3527.0% | -4332.7% | -4461.7% |
| Dec 2019 | $6.19M | N/A | -1122.0% | -1385.0% | -1380.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.04M | $0 | $0 | $1.56M | $1.26M | $1.49M | $6.19M |
| Cost of revenue | $17.05M | $7.19M | $76.55M | $8.26M | $61.34M | $54.08M | $75.60M |
| Gross profit | -$15.01M | -$7.19M | -$76.55M | -$6.69M | -$60.08M | -$52.59M | -$69.42M |
| Research and development | $69.30M | $88.60M | $76.55M | $63.26M | $61.34M | $54.08M | $75.60M |
| Operating income | -$107.44M | -$114.40M | -$100.05M | -$84.58M | -$81.21M | -$64.60M | -$85.69M |
| Net income | -$40.83M | -$148.70M | -$110.78M | -$11.96M | -$26.48M | -$66.52M | -$85.42M |
| EBITDA | -$22.24M | N/A | -$96.46M | $2.44M | -$13.89M | -$56.25M | -$78.94M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $406.00K | $495.00K | $467.00K | $753.00K | $301.00K | $517.00K | $7.23M | $0 | $0 | $0 | $10.79M | $0 |
| Gross profit | -$825.00K | -$1.54M | -$10.40M | -$1.37M | -$1.77M | -$1.46M | $3.61M | -$1.81M | -$1.82M | -$1.79M | -$3.38M | -$1.31M |
| Operating income | -$27.00M | -$28.93M | -$30.84M | -$24.39M | -$29.73M | -$23.18M | -$28.09M | -$30.23M | -$29.50M | -$26.58M | -$26.18M | -$24.62M |
| Net income | -$36.80M | -$17.62M | -$24.80M | -$17.51M | -$37.66M | $39.14M | -$20.94M | -$39.20M | -$56.66M | -$31.90M | -$25.11M | -$26.00M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $37.87M by $12.63M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $116.37M | $137.87M | $128.22M | $204.30M | $286.53M | $106.69M | $168.69M |
| Current assets | $67.80M | $47.86M | $83.28M | $154.21M | $229.34M | $41.45M | $94.95M |
| Cash and equivalents | $50.50M | $44.94M | $80.45M | $149.77M | $217.50M | $39.93M | $93.71M |
| Total liabilities | $113.26M | $190.54M | $114.68M | $87.37M | $164.36M | $36.02M | $36.49M |
| Short-term debt | $2.43M | $2.92M | $2.56M | $10.88M | $2.03M | $4.22M | $3.07M |
| Long-term debt | $35.44M | N/A | $38.60M | $20.34M | $27.36M | $822.00K | N/A |
| Shareholder equity | $3.11M | -$52.67M | $13.55M | $116.93M | $122.17M | $70.67M | $132.20M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $138.09M | $110.56M | $116.37M | $91.51M | $138.79M | $162.55M | $137.87M | $114.76M | $138.28M | $161.47M | $128.22M | $149.38M |
| Total liabilities | $106.83M | $98.93M | $113.26M | $96.26M | $134.74M | $126.51M | $190.54M | $178.49M | $166.57M | $135.31M | $114.68M | $112.39M |
| Cash and equivalents | $79.90M | $48.54M | $50.50M | $19.49M | $38.03M | $62.85M | $44.94M | $20.57M | $93.56M | $115.50M | $80.45M | $99.99M |
| Shareholder equity | $31.26M | $11.62M | $3.11M | -$4.75M | $4.05M | $36.04M | -$52.67M | -$63.72M | -$28.29M | $26.15M | $13.55M | $36.99M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -$81.19M | -$55.57M | -$71.79M |
| Capital expenditures | $884.00K | $1.57M | $2.28M | $1.05M | $220.00K | $318.00K | $8.13M |
| Free cash flow | -$105.93M | -$99.69M | -$75.58M | -$72.18M | -$81.41M | -$55.89M | -$79.91M |
| Investing cash flow | -$884.00K | -$1.57M | -$173.00K | $4.84M | -$8.22M | -$268.00K | -$8.13M |
| Financing cash flow | $61.49M | $114.18M | $4.51M | -$1.45M | $266.98M | $2.05M | -$74.00K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.06M | -$25.10M | -$26.12M | -$23.90M | -$26.41M | -$28.60M | -$26.58M | -$22.91M | -$21.29M | -$27.35M | -$19.05M | -$13.01M |
| Capital expenditures | $104.00K | $175.00K | $39.00K | $49.00K | $568.00K | $228.00K | $63.00K | $934.00K | $184.00K | $391.00K | $150.00K | $493.00K |
| Free cash flow | -$22.16M | -$25.28M | -$26.16M | -$23.95M | -$26.98M | -$28.83M | -$26.64M | -$23.84M | -$21.48M | -$27.74M | -$19.20M | -$13.50M |
Frequently Asked Questions About HUMAW
What is Humacyte's annual revenue?
Humacyte reported revenue of $2.04M for the fiscal year ended Dec 31, 2025.
Is Humacyte profitable?
No. Humacyte reported net income of -$40.83M for the fiscal year ended Dec 31, 2025, with a net margin of -2003.6%.
How much free cash flow does HUMAW generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$105.04M minus capital expenditures of $884.00K produced free cash flow of -$105.93M.
How much debt does Humacyte have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $35.44M, short-term debt of $2.43M and cash and equivalents of $50.50M.
What is HUMAW's profit margin?
For the fiscal year ended Dec 31, 2025, Humacyte reported gross margin of -736.5%, operating margin of -5271.7% and net margin of -2003.6%.
HUMAW pages: Overview, Financials